Clinical Trial Update: Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect [Phase 2, Phase 3]

View source ↗

Summary

The update reports on the duration of bone turnover suppression achieved with zoledronic acid in patients with metastatic breast cancer involving the bones, bas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Metastatic Breast Cancer With Bone Involvement | Phase 2, Phase 3 | Status: COMPLETED